SW480 cell line细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心

SW480 cell line细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心 货号： ab01589 ATCC Number： CCL-228™ 相关疾病： 大肠癌 细胞形态： 上皮样 生长状态： 贴壁生长 是否是肿瘤细胞： 1 物种来源： 人 数量： 大量 年限： Dukes' type B 运输方式： 冻存运输 器官来源： 结肠 Designations: SW480 [SW-480] Depositors: A Leibovitz Biosafety Level: 1 Shipped: frozen Medium & Serum: See Propagation Growth Properties: adherent Organism: Homo sapiens Morphology: epithelial Source: Organ: colon Tumor Stage: Dukes' type B Disease: colorectal adenocarcinoma Cellular Products: carcinoembryonic antigen (CEA) 0.7 ng/10 exp6 cells/10 days; keratin; transforming growth factor beta Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. Applications: transfection host Receptors: epidermal growth factor (EGF) Virus Susceptibility: Human immunodeficiency virus 1 Tumorigenic: Yes Oncogene: myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src - Antigen Expression: HLA A2, B8, B17; blood type A; Rh+ DNA Profile (STR): Amelogenin: X CSF1PO: 13,14 D13S317: 12 D16S539: 13 D5S818: 13 D7S820: 8 THO1: 8 TPOX: 11 vWA: 16 Cytogenetic Analysis: The stemline chromosome number is hypotriploid and 11-12 marker chromosomes were common. Both double minutes and dicentrics were observed in 8% of each metaphase examined. Isoenzymes: ES-D, 1 G6PD, B PEP-D, 1 PGD, A PGM1, 2 PGM3, 1 Age: 50 years Gender: male Ethnicity: Caucasian Comments: SW480 was established from a primary adenocarcinoma of the colon. A cell line established from a lymph node metastasis taken from the same patient one year later is available (see ATCC CCL-227). The line is negative for CSAp (CSAp-) and colon antigen 3. The cells are positive for keratin by immunoperoxidase staining. There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution and a C -> T mutation in codon 309 resulting in a Pro -> Ser substitution. The cells express elevated levels of p53 protein. The line is positive for expression of c-myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes. N-myc oncogene expression was not detected. Matrilysin, a metalloproteinase associated with tumor invasiveness, is not expressed. The cells have been reported to produce GM-CSF. This line has a mutation in codon 12 of the ras protooncogene, and can be used as a positive control for PCR assays of mutation in this codon. Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 100% Temperature: 37.0°C Subculturing: Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37�C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37�C. without CO2. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:8 is recommended Medium Renewal: 1 to 2 times per week Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008 recommended serum:ATCC 30-2020 derived from same individual:ATCC CCL-227 References: 22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080 22545: Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927 22564: Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832 22794: Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092 22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874 22870: Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460 22930: Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845 22996: Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498 23025: Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501 23071: Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289 23114: Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086 23322: Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228 25093: Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479 32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066 32925: Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224 49853: Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282
[Supplier来源] http://www.biovector.net